Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) have received a consensus rating of “Hold” from the eleven research firms that are covering the company, MarketBeat reports. Eight research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $15.25.

A number of equities research analysts have commented on the stock. Zacks Investment Research upgraded shares of PTC Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. BidaskClub cut shares of PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday. Citigroup Inc. set a $18.00 target price on shares of PTC Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 7th. Royal Bank Of Canada set a $12.00 target price on shares of PTC Therapeutics and gave the stock a “hold” rating in a research note on Monday, May 8th. Finally, J P Morgan Chase & Co restated a “neutral” rating and set a $21.00 target price (up previously from $15.00) on shares of PTC Therapeutics in a research note on Friday, June 30th.

ILLEGAL ACTIVITY WARNING: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/08/ptc-therapeutics-inc-nasdaqptct-receives-average-recommendation-of-hold-from-analysts.html.

In related news, Director Dawn Svoronos acquired 25,000 shares of PTC Therapeutics stock in a transaction dated Tuesday, May 23rd. The shares were purchased at an average price of $13.49 per share, for a total transaction of $337,250.00. Following the completion of the transaction, the director now directly owns 25,000 shares in the company, valued at approximately $337,250. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 8.10% of the company’s stock.

Several large investors have recently added to or reduced their stakes in PTCT. AXA bought a new stake in PTC Therapeutics during the first quarter valued at about $103,000. Nisa Investment Advisors LLC bought a new stake in PTC Therapeutics during the second quarter valued at about $125,000. Janney Montgomery Scott LLC bought a new stake in PTC Therapeutics during the first quarter valued at about $163,000. Virginia Retirement Systems ET AL bought a new stake in PTC Therapeutics during the first quarter valued at about $187,000. Finally, Prudential Financial Inc. bought a new stake in PTC Therapeutics during the second quarter valued at about $201,000. Hedge funds and other institutional investors own 77.00% of the company’s stock.

Shares of PTC Therapeutics (NASDAQ PTCT) traded down 4.07% during trading on Tuesday, reaching $19.10. 515,664 shares of the company traded hands. The company’s market capitalization is $655.44 million. PTC Therapeutics has a 52 week low of $4.03 and a 52 week high of $21.85. The company’s 50-day moving average price is $19.20 and its 200-day moving average price is $13.94.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. PTC Therapeutics had a negative net margin of 143.80% and a negative return on equity of 98.77%. The company had revenue of $26.50 million for the quarter, compared to analysts’ expectations of $27.93 million. During the same quarter last year, the business earned ($1.22) EPS. The firm’s revenue was up 40.2% compared to the same quarter last year. Equities research analysts forecast that PTC Therapeutics will post ($3.52) EPS for the current fiscal year.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Analyst Recommendations for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.